PHIL RIVERS TECHNOLOGY Co.,Ltd

A digital simulation platform for mining intrinsic mechanisms
of actions (MOAs) of drugs

Establishing digital models reflecting etiologies and pathologies of human diseases as well as pharmacology and MOAs of drugs

Virtual clinical trials

※    Accurate assessment of drug targets
※    Precise simulation of drug efficacy
※    Precisely pinpoint applicable indications
※    Accurately predicting responders to therapies

20

2025-04

Phil Rivers' PR00012 Completes First Patient Dosing with No DLTs Observed, Marking Key Phase I Trial Milestone

Beijing, April 20, 2025 — Dr. Jianfei Yang, President of R&D and Chief Scie···
26

2024-11

Revolutionary AI-Powered PR00012 Marks New Hope in Pancreatic Cancer Treatment, Receives IND Approval

Phil Rivers Technology today announced that its breakthrough candidate drug PR00···
11

2023-01

Senior immunologist Dr. Jianfei Yang joined PHIL RIVERS Technology as Chief Scientific Officer and debuted JPM Week

Recently, Phil Rivers Technology (Beijing) Ltd. announced that Dr. Jianfei Yang ···
27

2022-09

CAPR2022 | Phil Rivers Invited to Share New Practice of "AI+ Disease"

In recent years, the topic of AI drug development has received extensive attenti···
20

2022-09

2022 Hefei Scenario Innovation Conference | Phil Rivers annual best scenario Award

On September 16, 2022, the 1st China (Hefei) Scenario Innovation Conference spon···
10

2022-09

NIB | Phil Rivers won the award for Biomedical "Rising Star"

On September 7, 2022, the award ceremony of " Rising Star" of biomedic···
29

2022-08

CSDR and Relevant Units to Investigate "Computational Medicine"

CSDR and Relevant Units to Investigate "Computational Medicine"
29

2022-08

2022 Suzhou Dialogue | Phil Rivers Zhao Yu was invited to give an opening speech

On August 26, 2022, the special session "Production Quality Management in t···

A digital simulation platform for mining intrinsic mechanisms
of actions (MOAs) of drugs

Systematically delivering novel targets
and new MOAs of drugs

Virtual clinical trials

NEWS

20

2025-04

Phil Rivers' PR00012 Completes First Patient Dosing with No DLTs Observed, Marking Key Phase I Trial Milestone

26

2024-11

Revolutionary AI-Powered PR00012 Marks New Hope in Pancreatic Cancer Treatment, Receives IND Approval

11

2023-01

Senior immunologist Dr. Jianfei Yang joined PHIL RIVERS Technology as Chief Scientific Officer and debuted JPM Week

27

2022-09

CAPR2022 | Phil Rivers Invited to Share New Practice of "AI+ Disease"

20

2022-09

2022 Hefei Scenario Innovation Conference | Phil Rivers annual best scenario Award

10

2022-09

NIB | Phil Rivers won the award for Biomedical "Rising Star"

29

2022-08

CSDR and Relevant Units to Investigate "Computational Medicine"

29

2022-08

2022 Suzhou Dialogue | Phil Rivers Zhao Yu was invited to give an opening speech


	support@philrivers.com

	※ Beijing, China
	※ Shenzhen, China


	support@philrivers.com

	Beijing, China
	Shenzhen, China

A digital simulation platform for mining intrinsic mechanisms of actions (MOAs) of drugs

Systematically delivering novel targets and new MOAs of drugs

Virtual clinical trials

NEWS

20

2025-04

Phil Rivers' PR00012 Completes First Patient Dosing with No DLTs Observed, Marking Key Phase I Trial Milestone

26

2024-11

Revolutionary AI-Powered PR00012 Marks New Hope in Pancreatic Cancer Treatment, Receives IND Approval

11

2023-01

Senior immunologist Dr. Jianfei Yang joined PHIL RIVERS Technology as Chief Scientific Officer and debuted JPM Week

27

2022-09

CAPR2022 | Phil Rivers Invited to Share New Practice of "AI+ Disease"

20

2022-09

2022 Hefei Scenario Innovation Conference | Phil Rivers annual best scenario Award

10

2022-09

NIB | Phil Rivers won the award for Biomedical "Rising Star"

29

2022-08

CSDR and Relevant Units to Investigate "Computational Medicine"

29

2022-08

2022 Suzhou Dialogue | Phil Rivers Zhao Yu was invited to give an opening speech

A digital simulation platform for mining intrinsic mechanisms
of actions (MOAs) of drugs

Systematically delivering novel targets
and new MOAs of drugs